LU91624I2 - Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®) - Google Patents

Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)

Info

Publication number: LU91624I2
Authority: LU; Luxembourg
Prior art keywords: ilaris; canakinumab; pharmaceutically acceptable; acceptable derivatives; derivatives
Prior art date: 2000-08-22

Application number

LU91624C

Other languages

English (en)

Other versions

LU91624I9 (fr

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-22

Filing date

2009-11-25

Publication date

2010-01-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91624(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-25 Application filed by Novartis Ag filed Critical Novartis Ag

2010-01-25 Publication of LU91624I2 publication Critical patent/LU91624I2/fr

2018-11-19 Publication of LU91624I9 publication Critical patent/LU91624I9/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Neurosurgery (AREA)

LU91624C 2000-08-22 2009-11-25 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®) LU91624I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0020685.4A GB0020685D0 (en)	2000-08-22	2000-08-22	Organic compounds
PCT/EP2001/009588 WO2002016436A2 (fr)	2000-08-22	2001-08-20	ANTICORPS DE LA IL-1β HUMAINE

Publications (2)

Publication Number	Publication Date
LU91624I2 true LU91624I2 (fr)	2010-01-25
LU91624I9 LU91624I9 (fr)	2018-11-19

Family

ID=9898090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91624C LU91624I2 (fr)	2000-08-22	2009-11-25	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)

Country Status (36)

Country	Link
US (3)	US7446175B2 (fr)
EP (1)	EP1313769B2 (fr)
JP (2)	JP4271936B2 (fr)
KR (2)	KR100910789B1 (fr)
CN (1)	CN100547003C (fr)
AR (1)	AR035581A1 (fr)
AT (1)	ATE396206T1 (fr)
AU (2)	AU2001295490B2 (fr)
BE (1)	BE2009C057I2 (fr)
BR (1)	BR0113420A (fr)
CA (1)	CA2420231C (fr)
CY (2)	CY1108779T1 (fr)
CZ (1)	CZ304470B6 (fr)
DE (2)	DE60134148D1 (fr)
DK (1)	DK1313769T4 (fr)
EC (1)	ECSP034490A (fr)
ES (1)	ES2305110T5 (fr)
FR (1)	FR09C0062I2 (fr)
GB (1)	GB0020685D0 (fr)
HU (2)	HU228159B1 (fr)
IL (2)	IL154465A0 (fr)
LU (1)	LU91624I2 (fr)
MX (1)	MXPA03001590A (fr)
MY (1)	MY130248A (fr)
NL (1)	NL300427I1 (fr)
NO (3)	NO332609B1 (fr)
NZ (2)	NZ534269A (fr)
PE (1)	PE20020319A1 (fr)
PL (1)	PL212480B1 (fr)
PT (1)	PT1313769E (fr)
RU (1)	RU2286351C2 (fr)
SI (1)	SI1313769T2 (fr)
SK (1)	SK288089B6 (fr)
TW (1)	TWI321568B (fr)
WO (1)	WO2002016436A2 (fr)
ZA (1)	ZA200301275B (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001297702A1 (en) *	2000-11-08	2002-10-15	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
US7348003B2 (en)	2001-05-25	2008-03-25	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en)	2001-05-25	2008-04-22	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
CN104178491B (zh)	2002-09-06	2018-07-03	安姆根有限公司	治疗性人抗-il-1r1单克隆抗体
US7101978B2 (en) *	2003-01-08	2006-09-05	Applied Molecular Evolution	TNF-α binding molecules
CA2509136C (fr) *	2003-01-24	2013-10-29	Applied Molecular Evolution, Inc.	Antagonistes de l'il-1 beta humaine
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
US20040224893A1 (en) *	2003-05-06	2004-11-11	Li-Hsien Wang	Methods of using IL-1 antagonists to treat neointimal hyperplasia
NZ549040A (en)	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP4989456B2 (ja) *	2004-02-26	2012-08-01	ベイラーリサーチインスティテュート	関節炎の全身処置のための組成物および方法
EP2361933A3 (fr) *	2005-01-26	2012-05-02	Amgen Fremont Inc.	Anticorps contre l'interleukine-1 bêta
AU2012213934B9 (en) *	2005-01-26	2013-07-25	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
GB0509512D0 (en) *	2005-05-10	2005-06-15	Novartis Ag	Organic compounds
ES2335232T3 (es)	2005-06-21	2010-03-23	Xoma Technology Ltd.	Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
WO2007042524A2 (fr) *	2005-10-14	2007-04-19	Novo Nordisk A/S	Traitement du diabete a l'aide d'inhibiteurs de l'il-1
JP2009513645A (ja) *	2005-10-26	2009-04-02	ノバルティスアクチエンゲゼルシャフト	ＩＬ−１β化合物の新規使用
EP2021026A1 (fr) *	2006-04-14	2009-02-11	Novartis AG	Utilisation d'anticorps anti-il-1 pour le traitement de troubles ophtalmiques
CA2673592C (fr)	2006-12-20	2014-03-25	Xoma Technology Ltd.	Procedes de traitement de maladies associees a il-.beta.
CL2008001071A1 (es) *	2007-04-17	2009-05-22	Smithkline Beecham Corp	Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
EP1997832A1 (fr) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
JP2010528086A (ja)	2007-05-29	2010-08-19	ノバルティスアーゲー	抗ｉｌ−１治療に関する新しい適応症
EP2391650B1 (fr)	2007-12-20	2014-10-15	Xoma (Us) Llc	Procédés pour le traitement de la goutte
CN102076355B (zh)	2008-04-29	2014-05-07	Abbvie公司	双重可变结构域免疫球蛋白及其用途
US9109026B2 (en) *	2008-06-03	2015-08-18	Abbvie, Inc.	Dual variable domain immunoglobulins and uses thereof
TW201008580A (en)	2008-06-03	2010-03-01	Abbott Lab	Dual variable domain immunoglobulin and uses thereof
JP5607613B2 (ja) *	2008-06-06	2014-10-15	ゾーマ（ユーエス）リミテッドライアビリティカンパニー	関節リウマチの治療のための方法
JP5674654B2 (ja)	2008-07-08	2015-02-25	アッヴィ・インコーポレイテッド	プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
WO2010028275A1 (fr) *	2008-09-05	2010-03-11	Xoma Technology Ltd.	Procédés pour le traitement ou la prévention des maladies associées à il-1ss
AU2009307728B2 (en) *	2008-10-20	2014-12-11	Abbvie Inc.	Antibodies that bind to IL-18 and methods of purifying the same
US8298533B2 (en) *	2008-11-07	2012-10-30	Medimmune Limited	Antibodies to IL-1R1
EP2196476A1 (fr) *	2008-12-10	2010-06-16	Novartis Ag	Formulation d'anticorps
US20130122008A1 (en) *	2009-05-06	2013-05-16	Novartis Ag	Anti-IL 1- ß Antibody Combination Therapy
US8389474B1 (en) *	2009-07-14	2013-03-05	Alan Anson Wanderer	Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
NZ598929A (en) *	2009-09-01	2014-05-30	Abbvie Inc	Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (pt) *	2009-10-15	2015-09-08	Abbott Lab	imunoglobulinas de dominio variavel duplo e usos das mesmas
MX2012004682A (es)	2009-10-26	2012-09-07	Hoffmann La Roche	Metodo para la produccion de una inmunoglobulina glicosilada.
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
PH12012502143A1 (en) *	2010-05-07	2019-07-03	Xoma Us Llc	Methods for the treatment of il-1beta related conditions
PE20131412A1 (es)	2010-08-03	2014-01-19	Abbvie Inc	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2608803A4 (fr)	2010-08-26	2014-01-15	Abbvie Inc	Immunoglobulines à deux domaines variables et leurs utilisations
CN103492416A (zh)	2011-04-15	2014-01-01	默克专利股份公司	用于癌症中使用的抗il-1r1抑制剂
US9707272B2 (en)	2011-07-12	2017-07-18	Universitat Zurich	Method for the treatment of acne by administering IL-1β antibody
DE102011083595A1 (de)	2011-09-28	2013-03-28	Bayer Pharma AG	Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
BR112014007253A2 (pt)	2011-09-30	2017-03-28	Novartis Ag	uso de anticorpos que se ligam a il-1beta
US20140348848A1 (en)	2011-12-02	2014-11-27	Dhananjay Kaul	Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CN107459576A (zh) *	2011-12-14	2017-12-12	艾伯维德国有限责任两合公司	用于诊断和治疗铁相关病症的组合物和方法
WO2013087914A1 (fr)	2011-12-16	2013-06-20	Synthon Biopharmaceuticals B.V.	Expression d'anticorps iga sécrétoires chez la lentille d'eau
EP3050900A1 (fr)	2011-12-19	2016-08-03	Xoma (Us) Llc	Procédés pour le traitement de l'acnée
UY34558A (es)	2011-12-30	2013-07-31	Abbvie Inc	Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
SG11201404850SA (en) *	2012-02-13	2014-09-26	Agency Science Tech & Res	IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
CN103588878A (zh) *	2012-08-15	2014-02-19	江苏泰康生物医药有限公司	一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
KR20190096459A (ko)	2012-11-01	2019-08-19	애브비 인코포레이티드	항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
PL2914287T3 (pl)	2012-11-05	2020-09-07	Delenex Therapeutics Ag	Elementy wiążące się z il-1 beta
AU2013344796B2 (en)	2012-11-16	2016-11-10	Novartis Ag	Use of IL-1 beta binding antibodies for treating peripheral arterial disease
ES2895848T3 (es)	2012-12-17	2022-02-22	Cell Medica Inc	Anticuerpos contra IL-1 beta
KR20150095684A (ko)	2012-12-18	2015-08-21	노파르티스 아게	히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
BR112015023797A2 (pt)	2013-03-15	2017-10-24	Abbvie Inc	proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
WO2015083120A1 (fr)	2013-12-04	2015-06-11	Novartis Ag	Utilisation d'anticorps de liaison à il-1β
EP3160991A2 (fr)	2014-06-25	2017-05-03	Novartis AG	Compositions et procédés permettant d'obtenir des protéines à action prolongée
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
WO2016008851A1 (fr) *	2014-07-14	2016-01-21	Boehringer Ingelheim International Gmbh	Anticorps anti-il-1b
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6877339B2 (ja)	2014-10-14	2021-05-26	ノバルティスアーゲー	Ｐｄ−ｌ１に対する抗体分子およびその使用
WO2016075037A1 (fr)	2014-11-10	2016-05-19	F. Hoffmann-La Roche Ag	Anticorps bispécifiques et procédés d'utilisation en ophtalmologie
WO2016075035A1 (fr)	2014-11-10	2016-05-19	F. Hoffmann-La Roche Ag	Anticorps anti-ang2 et méthodes d'utilisation correspondantes
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
EP3303388A1 (fr)	2015-06-04	2018-04-11	Novartis AG	Utilisation d'anticorps de liaison il-1 bêta pour traiter une maladie artérielle périphérique
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017019896A1 (fr)	2015-07-29	2017-02-02	Novartis Ag	Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
EP3964528A1 (fr)	2015-07-29	2022-03-09	Novartis AG	Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
EP3878465A1 (fr)	2015-07-29	2021-09-15	Novartis AG	Polythérapies comprenant des molécules d'anticorps tim-3
EP4424322A3 (fr)	2015-12-17	2025-04-16	Novartis AG	Molécules d'anticorps anti-pd-1 et leurs utilisations
US11377656B2 (en)	2016-03-10	2022-07-05	Novartis Ag	Chemically modified messenger RNA's
JP2019521161A (ja)	2016-07-21	2019-07-25	ノバルティスアーゲー	肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用
EP4252629A3 (fr)	2016-12-07	2023-12-27	Biora Therapeutics, Inc.	Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
WO2018112256A1 (fr)	2016-12-14	2018-06-21	Progenity Inc.	Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-1
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
KR20200019865A (ko)	2017-06-22	2020-02-25	노파르티스 아게	암 치료에 사용하기 위한 il-1베타 결합 항체
WO2018235056A1 (fr)	2017-06-22	2018-12-27	Novartis Ag	Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
US20200158716A1 (en) *	2017-07-17	2020-05-21	Massachusetts Institute Of Technology	Cell atlas of healthy and diseased barrier tissues
EP3710476A1 (fr)	2017-08-25	2020-09-23	Novartis AG	Utilisation de canakinumab
BR112020004903A2 (pt) *	2017-09-13	2020-09-15	Novartis Ag	uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica
CA3081602A1 (fr)	2017-11-16	2019-05-23	Novartis Ag	Polytherapies
JP2021523894A (ja) *	2018-05-09	2021-09-09	ノバルティスアーゲー	カナキヌマブの使用
US11492409B2 (en)	2018-06-01	2022-11-08	Novartis Ag	Binding molecules against BCMA and uses thereof
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB2575853A (en) *	2018-07-25	2020-01-29	Robert Wotherspoon Hugh	IL-1ß binding antibody
CN110818793A (zh)	2018-08-14	2020-02-21	中山康方生物医药有限公司	抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Traitement comprenant des anticorps se liant à il-1 βeta et ses combinaisons
JP7256266B2 (ja) *	2018-11-07	2023-04-11	沢達生物医薬有限公司	ヒトＩＬ－１βに結合する抗体、その調製方法及び用途
US20220249814A1 (en)	2018-11-19	2022-08-11	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
EP3897637A1 (fr)	2018-12-20	2021-10-27	Novartis AG	Schéma posologique et combinaison pharmaceutique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione
US20220025036A1 (en)	2018-12-21	2022-01-27	Novartis Ag	Use of il-1beta binding antibodies
GB201901187D0 (en)	2019-01-29	2019-03-20	Autolus Ltd	Treatment of neurotoxicity and/or cytokine release syndrome
ES2982474T3 (es)	2019-02-15	2024-10-16	Novartis Ag	Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
CN113490528B (zh)	2019-02-15	2024-12-03	诺华股份有限公司	3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20220356240A1 (en) *	2019-09-26	2022-11-10	Beth Israel Deaconess Medical Center, Inc.	Anti-inflammatory therapy in arrhythmogenic cardiomyopathy (acm)
US20230020548A1 (en)	2019-12-09	2023-01-19	Novartis Ag	Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
EP4309722A3 (fr)	2019-12-13	2024-08-07	Biora Therapeutics, Inc.	Dispositif ingérable pour l'administration d'un agent thérapeutique au tractus gastro-intestinal
IL293889A (en)	2019-12-20	2022-08-01	Novartis Ag	Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
TWI793503B (zh)	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
US12486321B2 (en)	2020-01-21	2025-12-02	Tavotek Biotechnology (Jiangsu) Co., Ltd	Agents that interfere with IL-1BETA receptor signalling
WO2021231798A1 (fr)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anticorps anti-hémojuvéline (hjv) pour le traitement de la myélofibrose
US20230220065A1 (en) *	2020-06-16	2023-07-13	Academia Sinica	Antibodies to interleukin-1beta and uses thereof
WO2021260528A1 (fr)	2020-06-23	2021-12-30	Novartis Ag	Schéma posologique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione
WO2022023907A1 (fr)	2020-07-31	2022-02-03	Novartis Ag	Méthodes de sélection et de traitement de patients présentant un risque élevé d'événements cardiaques indésirables majeurs
EP4240491A1 (fr)	2020-11-06	2023-09-13	Novartis AG	Molécules de liaison à cd19 et utilisations associées
US12441786B2 (en)	2020-11-18	2025-10-14	Novartis Ag	Bispecific antibodies for use in treatment of NLRC4-GOF inflammasomapathy
WO2022167916A1 (fr)	2021-02-03	2022-08-11	Novartis Ag	Utilisation d'anticorps se liant à l'il-1b pour le traitement de troubles neuro-inflammatoires
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
JP2024519893A (ja)	2021-05-24	2024-05-21	ノバルティスアーゲー	変形性関節症の治療方法
US20240294626A1 (en)	2021-06-22	2024-09-05	Novartis Ag	Bispecific antibodies for use in treatment of hidradenitis suppurativa
WO2025068957A1 (fr)	2023-09-29	2025-04-03	Novartis Ag	Anticorps bispécifiques destinés à être utilisés dans l'abaissement du risque d'événements de maladie cardiovasculaire chez des sujets connus pour être un support d'expansion clonale de lignées cellulaires hématopoïétiques avec des mutations somatiques
GB202400340D0 (en)	2024-01-10	2024-02-21	Wotherspoon Hugh Robert	IL-1B binding antibody

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US534858A (en) *		1895-02-26		Workman s time-recorder
CA1172789A (fr)	1980-09-25	1984-08-14	Hideo Kasahara	POLYMERE RENFERMANT UN POLYAMIDE LIE A UN COPOLYMERE QUI CONTIENT UN IMIDE D'ACIDE CARBOXYLIQUE INSATURE EN .alpha.,.beta.
US4772685A (en)	1985-10-02	1988-09-20	Merck & Co., Inc.	Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4935343A (en) *	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
WO1988001649A1 (fr)	1986-09-02	1988-03-10	Genex Corporation	Molecules de liaison de chaines de polypeptide simples
DK590387A (da)	1986-11-13	1988-05-14	Otsuka Pharma Co Ltd	Antistoffer mod interleukin-1
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
DE68925935T2 (de) *	1988-10-01	1996-08-14	Otsuka Pharma Co Ltd	Antikörper gegen Interleukin-1-beta
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
FR2640146B1 (fr)	1988-12-08	1993-12-24	Commissariat A Energie Atomique	Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (fr)	1989-06-07	1990-12-07	Clyde W. Shearman	Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
JP3714683B2 (ja)	1992-07-30	2005-11-09	生化学工業株式会社	抗リウマチ剤
US5429614A (en)	1993-06-30	1995-07-04	Baxter International Inc.	Drug delivery system
WO1995001997A1 (fr) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en)	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
GB0001448D0 (en)	2000-01-21	2000-03-08	Novartis Ag	Organic compounds

2000
- 2000-08-22 GB GBGB0020685.4A patent/GB0020685D0/en not_active Ceased
2001
- 2001-08-16 PE PE2001000817A patent/PE20020319A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103946A patent/AR035581A1/es active IP Right Grant
- 2001-08-20 NZ NZ534269A patent/NZ534269A/en not_active IP Right Cessation
- 2001-08-20 AU AU2001295490A patent/AU2001295490B2/en not_active Expired
- 2001-08-20 SI SI200130844T patent/SI1313769T2/sl unknown
- 2001-08-20 MX MXPA03001590A patent/MXPA03001590A/es active IP Right Grant
- 2001-08-20 SK SK213-2003A patent/SK288089B6/sk not_active IP Right Cessation
- 2001-08-20 PT PT01976118T patent/PT1313769E/pt unknown
- 2001-08-20 DE DE60134148T patent/DE60134148D1/de not_active Expired - Lifetime
- 2001-08-20 PL PL360358A patent/PL212480B1/pl unknown
- 2001-08-20 KR KR1020037002161A patent/KR100910789B1/ko not_active Expired - Lifetime
- 2001-08-20 DE DE122009000078C patent/DE122009000078I1/de active Pending
- 2001-08-20 HU HU0300806A patent/HU228159B1/hu active Protection Beyond IP Right Term
- 2001-08-20 ES ES01976118T patent/ES2305110T5/es not_active Expired - Lifetime
- 2001-08-20 US US10/362,082 patent/US7446175B2/en not_active Expired - Lifetime
- 2001-08-20 RU RU2003107564/13A patent/RU2286351C2/ru active Protection Beyond IP Right Term
- 2001-08-20 AU AU9549001A patent/AU9549001A/xx active Pending
- 2001-08-20 JP JP2002521531A patent/JP4271936B2/ja not_active Expired - Lifetime
- 2001-08-20 DK DK01976118.8T patent/DK1313769T4/da active
- 2001-08-20 CN CNB018145140A patent/CN100547003C/zh not_active Expired - Lifetime
- 2001-08-20 BR BR0113420-5A patent/BR0113420A/pt not_active IP Right Cessation
- 2001-08-20 CA CA2420231A patent/CA2420231C/fr not_active Expired - Lifetime
- 2001-08-20 WO PCT/EP2001/009588 patent/WO2002016436A2/fr not_active Ceased
- 2001-08-20 NZ NZ524199A patent/NZ524199A/en not_active IP Right Cessation
- 2001-08-20 CZ CZ2003-505A patent/CZ304470B6/cs not_active IP Right Cessation
- 2001-08-20 AT AT01976118T patent/ATE396206T1/de active
- 2001-08-20 IL IL15446501A patent/IL154465A0/xx unknown
- 2001-08-20 KR KR1020087012282A patent/KR20080056316A/ko not_active Ceased
- 2001-08-20 EP EP01976118A patent/EP1313769B2/fr not_active Expired - Lifetime
- 2001-08-21 MY MYPI20013927A patent/MY130248A/en unknown
- 2001-08-22 TW TW090120626A patent/TWI321568B/zh not_active IP Right Cessation
2003
- 2003-02-13 IL IL154465A patent/IL154465A/en active Protection Beyond IP Right Term
- 2003-02-17 ZA ZA200301275A patent/ZA200301275B/en unknown
- 2003-02-19 EC EC2003004490A patent/ECSP034490A/es unknown
- 2003-02-21 NO NO20030827A patent/NO332609B1/no not_active IP Right Cessation
2008
- 2008-08-01 JP JP2008199799A patent/JP2008295456A/ja active Pending
- 2008-08-11 CY CY20081100840T patent/CY1108779T1/el unknown
- 2008-09-26 US US12/238,502 patent/US7993878B2/en not_active Expired - Fee Related
2009
- 2009-11-24 NL NL300427C patent/NL300427I1/nl unknown
- 2009-11-25 LU LU91624C patent/LU91624I2/fr unknown
- 2009-11-30 BE BE2009C057C patent/BE2009C057I2/fr unknown
- 2009-12-03 FR FR09C0062C patent/FR09C0062I2/fr active Active
- 2009-12-09 CY CY2009019C patent/CY2009019I2/el unknown
2011
- 2011-06-29 US US13/171,631 patent/US8273350B2/en not_active Expired - Fee Related
2012
- 2012-11-21 NO NO2012018C patent/NO2012018I1/no unknown
2013
- 2013-04-26 HU HUS1300015C patent/HUS1300015I1/hu unknown
2017
- 2017-10-11 NO NO2017052C patent/NO2017052I2/no unknown

Also Published As

Publication number	Publication date
HUP0300806A2 (hu)	2003-12-29
BRPI0113420B8 (fr)	2021-05-25
NO2012018I2 (no)	2012-11-21
US20090081732A1 (en)	2009-03-26
IL154465A0 (en)	2003-09-17
EP1313769A2 (fr)	2003-05-28
FR09C0062I2 (fr)	2010-12-31
NO332609B1 (no)	2012-11-19
DE122009000078I1 (de)	2010-03-25
JP4271936B2 (ja)	2009-06-03
DK1313769T4 (da)	2011-12-05
LU91624I9 (fr)	2018-11-19
NZ534269A (en)	2006-04-28
ES2305110T5 (es)	2012-03-13
CY2009019I1 (el)	2012-01-25
CZ2003505A3 (cs)	2003-05-14
CY2009019I2 (el)	2017-07-12
FR09C0062I1 (fr)	2010-08-01
NO20030827L (no)	2003-04-14
WO2002016436A2 (fr)	2002-02-28
HK1061403A1 (en)	2004-09-17
AR035581A1 (es)	2004-06-16
US7993878B2 (en)	2011-08-09
EP1313769B2 (fr)	2011-11-09
US20110256151A1 (en)	2011-10-20
NZ524199A (en)	2004-09-24
US7446175B2 (en)	2008-11-04
CA2420231A1 (fr)	2002-02-28
WO2002016436A3 (fr)	2002-06-20
BRPI0113420B1 (pt)	2002-02-28
AU2001295490B2 (en)	2005-06-16
PL212480B1 (pl)	2012-10-31
DE60134148D1 (de)	2008-07-03
PT1313769E (pt)	2008-08-26
NO2017052I2 (no)	2018-05-14
MY130248A (en)	2007-06-29
NL300427I2 (en)	2010-02-01
ATE396206T1 (de)	2008-06-15
KR20030034140A (ko)	2003-05-01
KR20080056316A (ko)	2008-06-20
PE20020319A1 (es)	2002-06-11
BE2009C057I2 (fr)	2021-01-28
DK1313769T3 (da)	2008-09-15
RU2286351C2 (ru)	2006-10-27
HUP0300806A3 (en)	2005-09-28
HU228159B1 (en)	2013-01-28
SK288089B6 (sk)	2013-06-03
NO2017052I1 (no)	2017-10-11
SI1313769T1 (sl)	2008-10-31
PL360358A1 (en)	2004-09-06
TWI321568B (en)	2010-03-11
BR0113420A (pt)	2003-07-29
CZ304470B6 (cs)	2014-05-21
GB0020685D0 (en)	2000-10-11
HUS1300015I1 (hu)	2021-05-28
ZA200301275B (en)	2004-04-02
ES2305110T3 (es)	2008-11-01
NL300427I1 (en)	2010-02-01
CY1108779T1 (el)	2012-01-25
CN1484652A (zh)	2004-03-24
US8273350B2 (en)	2012-09-25
MXPA03001590A (es)	2003-06-04
SI1313769T2 (sl)	2012-01-31
CA2420231C (fr)	2011-04-26
JP2008295456A (ja)	2008-12-11
KR100910789B1 (ko)	2009-08-04
IL154465A (en)	2010-11-30
NO20030827D0 (no)	2003-02-21
AU9549001A (en)	2002-03-04
EP1313769B1 (fr)	2008-05-21
JP2004506448A (ja)	2004-03-04
SK2132003A3 (en)	2003-10-07
ECSP034490A (es)	2003-03-31
CN100547003C (zh)	2009-10-07
US20040063913A1 (en)	2004-04-01
NO2012018I1 (no)	2012-12-10

Publication	Publication Date	Title
LU91624I2 (fr)	2010-01-25	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU92381I2 (fr)	2014-04-28	Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU92024I2 (fr)	2012-08-20	Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU91757I2 (fr)	2011-01-24	Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
LU92513I2 (fr)	2015-11-02	Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU92419I2 (fr)	2014-06-02	Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU92336I2 (fr)	2014-02-17	Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU92745I2 (fr)	2015-08-17	Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU91882I2 (fr)	2013-04-12	Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU93093I2 (fr)	2016-08-01	Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU91269I2 (fr)	2006-09-26	Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
LU91346I2 (fr)	2007-09-11	Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU91883I2 (fr)	2013-04-12	Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
CY2013011I1 (el)	2015-08-05	Μεθοδος χορηγησης διφωσφονικων
LU92871I2 (fr)	2016-01-13	Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LU91122I2 (fr)	2005-01-10	Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU91673I2 (fr)	2010-06-07	"Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
IS1940B (is)	2004-07-16	Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
AU2002230764A1 (en)	2002-06-24	Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
LU91501I2 (fr)	2009-01-26	Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
DE60142197D1 (de)	2010-07-01	Pharmazeutische Zusammensetzung
LU91076I2 (fr)	2004-07-05	Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU91189I2 (fr)	2005-10-03	Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
LU91875I2 (fr)	2011-11-21	Formoterolfumarate et dipropionate de beclomethasone et leurs sels et dérivés pharmaceutiquement acceptables
LU91251I2 (fr)	2006-08-14	Vaccin à rotavirus (vivant) et ses dérivés pharmaceutiquement acceptables (ROTARIXr)